Trinity Biotech Files Routine 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Dec 26, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
Trinity Biotech filed a standard 6-K, no new news.
AI Summary
Trinity Biotech plc filed a Form 6-K on December 26, 2024, reporting for the month of December 2024. The company, based in Dublin, Ireland, is a foreign private issuer and will file its annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates beyond its routine reporting status.
Why It Matters
This filing indicates Trinity Biotech plc is fulfilling its regular reporting obligations as a foreign private issuer with the SEC. It does not contain new material information.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain any new material information or financial updates.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- 0000888721 (company) — Central Index Key
- 2835 (company) — Standard Industrial Classification Code
- December 2024 (date) — Reporting Period
- 20241226 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the registrant for this filing?
The registrant is TRINITY BIOTECH PLC.
What is the reporting period for this Form 6-K?
The reporting period is for the month of December 2024.
Does Trinity Biotech file under Form 20-F or 40-F?
Trinity Biotech indicates it files annual reports under cover of Form 20-F.
Where is Trinity Biotech's principal executive office located?
The principal executive office is located at IDA Business Park, Bray, Co. Wicklow, Ireland.
Filing Stats: 401 words · 2 min read · ~1 pages · Grade level 13.8 · Accepted 2024-12-26 07:12:51
Filing Documents
- zk2432488.htm (6-K) — 15KB
- exhibit_99-1.htm (EX-99.1) — 796KB
- exhibit_99-2.htm (EX-99.2) — 13KB
- image0.jpg (GRAPHIC) — 90KB
- 0001178913-24-004052.txt ( ) — 950KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: December 26, 2024